Septic shock is a common and life-threatening condition associated with an in-hospital mortality rate exceeding 40%. The symptomatic management of septic shock relies primarily on vasopressor therapy, particularly norepinephrine. However, the use of high doses of norepinephrine may lead to adverse effects, prompting the search for alternative therapeutic strategies, including angiotensin II, which has recently been investigated as an adjunctive vasopressor. Indeed, alterations of the renin-angiotensin-aldosterone system (RAAS), particularly a relative deficiency of angiotensin II, have been hypothesized to occur during septic shock. However, to date, no human study has used gold-standard techniques for measuring RAAS peptides to confirm this hypothesis. Furthermore, it remains unclear whether these alterations are specific to septic shock or may also be observed in less severe infections (sepsis) or in other forms of circulatory failure, such as cardiogenic shock.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
320
blood sample and urinary
To determine the incidence of relative angiotensin II deficiency during septic shock
The incidence of relative angiotensin II deficiency at the different study time points (6, 24, and 72 hours), defined as a circulating angiotensin II concentration below or equal to the 95th percentile of healthy subjects in the presence of arterial hypotension (mean arterial pressure \< 65 mmHg) or the need for vasopressor support to maintain a mean arterial pressure \> 65 mmHg. This definition is similar to that used in previous studies to define relative vasopressin deficiency during septic shock.
Time frame: From enrollment to 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.